Mylan to Pay Abbott $5.3 Billion for Non-US Business

Generic drugmaker Mylan said it plans to acquire Abbott Laboratories' branded specialty and generics business in developed markets outside the US for $5.3 billion. Both companies are US-based.

The buy gives Mylan a wide array of Abbott brands that have annual sales of almost $2 billion in those markets, including gastroenterology drug Creon,  pain drug Brufen and influenza vaccine Influvac.

The deal has been structured to help Mylan reduce its tax bill by moving its tax address outside the US, a process known as inversion. The company with headquarters in Pittsburgh, Pennsylvania, unsuccessfully pursued the Swedish drug maker Meda this year in hopes of engaging in an inversion.

"We have been actively looking at a wide range of opportunities, and the acquisition of this business is absolutely the right next strategic transaction for Mylan as it builds on our strong momentum, expands and further diversifies our business in our largest markets outside of the US," executive chairman Robert J. Coury said in a statement.

The transaction foresees Abbott taking a 21% stake in a new company that combines Mylan's existing business with its own developed markets pharmaceuticals operations in Europe, Japan, Canada, Australia and New Zealand.

Abbott will continue to sell its branded generics in emerging markets, where strong sales growth is expected because of rising numbers of middle-class patients. By contrast, its sales of generics in developed markets have been steadily declining in recent years due to price pressures in Europe.

Abbot said it plans to relatively quickly sell its stake in the new company and use the proceeds to boost earnings, possibly by acquiring more medical devices or buying back shares.

A successful transaction would give Mylan a portfolio of more than 100 specialty and branded generic pharmaceutical products in five major therapeutic areas including cardio-metabolic and gastrointestinal.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.